BIOMAT Database Logo BIOMAT Database Logo

Dormant cancer cells accumulate high protoporphyrin IX levels and are sensitive to 5-aminolevulinic acid-based photodynamic therapy. 2016

Taku Nakayama, and Shimpei Otsuka, and Tatsuya Kobayashi, and Hodaka Okajima, and Kentaro Matsumoto, and Yuichiro Hagiya, and Keiji Inoue, and Taro Shuin, and Motowo Nakajima, and Tohru Tanaka, and Shun-Ichiro Ogura
Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, 4259 B47, Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan.

Photodynamic therapy (PDT) and diagnosis (PDD) using 5-aminolevulinic acid (ALA) to drive the production of an intracellular photosensitizer, protoporphyrin IX (PpIX), are in common clinical use. However, the tendency to accumulate PpIX is not well understood. Patients with cancer can develop recurrent metastatic disease with latency periods. This pause can be explained by cancer dormancy. Here we created uniformly sized PC-3 prostate cancer spheroids using a 3D culture plate (EZSPHERE). We demonstrated that cancer cells exhibited dormancy in a cell density-dependent manner not only in spheroids but also in 2D culture. Dormant cancer cells accumulated high PpIX levels and were sensitive to ALA-PDT. In dormant cancer cells, transporter expressions of PEPT1, ALA importer, and ABCB6, an intermediate porphyrin transporter, were upregulated and that of ABCG2, a PpIX exporter, was downregulated. PpIX accumulation and ALA-PDT cytotoxicity were enhanced by G0/G1-phase arrestors in non-dormant cancer cells. Our results demonstrate that ALA-PDT would be an effective approach for dormant cancer cells and can be enhanced by combining with a cell-growth inhibitor.

UI MeSH Term Description Entries
D008297 Male Males
D010778 Photochemotherapy Therapy using oral or topical photosensitizing agents with subsequent exposure to light. Blue Light Photodynamic Therapy,Photodynamic Therapy,Red Light PDT,Red Light Photodynamic Therapy,Therapy, Photodynamic,Light PDT, Red,PDT, Red Light,Photochemotherapies,Photodynamic Therapies,Therapies, Photodynamic
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011524 Protoporphyrins Porphyrins with four methyl, two vinyl, and two propionic acid side chains attached to the pyrrole rings. Protoporphyrin IX occurs in hemoglobin, myoglobin, and most of the cytochromes.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000622 Aminolevulinic Acid A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS. 5-Amino Levulinic Acid,5-Aminolaevulinate,5-Aminolevulinate,Aminolevulinic Acid Hydrochloride,Delta-Aminolevulinic Acid,Levulan,5 Amino Levulinic Acid,5 Aminolaevulinate,5 Aminolevulinate,Acid Hydrochloride, Aminolevulinic,Acid, 5-Amino Levulinic,Acid, Aminolevulinic,Acid, Delta-Aminolevulinic,Delta Aminolevulinic Acid,Hydrochloride, Aminolevulinic Acid,Levulinic Acid, 5-Amino
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D017319 Photosensitizing Agents Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. Photosensitizer,Photosensitizers,Photosensitizing Agent,Photosensitizing Effect,Photosensitizing Effects,Agent, Photosensitizing,Agents, Photosensitizing,Effect, Photosensitizing,Effects, Photosensitizing
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Taku Nakayama, and Shimpei Otsuka, and Tatsuya Kobayashi, and Hodaka Okajima, and Kentaro Matsumoto, and Yuichiro Hagiya, and Keiji Inoue, and Taro Shuin, and Motowo Nakajima, and Tohru Tanaka, and Shun-Ichiro Ogura
eEF1A1 binds and enriches protoporphyrin IX in cancer cells in 5-aminolevulinic acid based photodynamic therapy.
May 2016, Scientific reports,
Taku Nakayama, and Shimpei Otsuka, and Tatsuya Kobayashi, and Hodaka Okajima, and Kentaro Matsumoto, and Yuichiro Hagiya, and Keiji Inoue, and Taro Shuin, and Motowo Nakajima, and Tohru Tanaka, and Shun-Ichiro Ogura
Increase in protoporphyrin IX after 5-aminolevulinic acid based photodynamic therapy is due to local re-synthesis.
August 2007, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology,
Taku Nakayama, and Shimpei Otsuka, and Tatsuya Kobayashi, and Hodaka Okajima, and Kentaro Matsumoto, and Yuichiro Hagiya, and Keiji Inoue, and Taro Shuin, and Motowo Nakajima, and Tohru Tanaka, and Shun-Ichiro Ogura
Two-photon photodynamic therapy of C6 cells by means of 5-aminolevulinic acid induced protoporphyrin IX.
June 2007, Journal of photochemistry and photobiology. B, Biology,
Taku Nakayama, and Shimpei Otsuka, and Tatsuya Kobayashi, and Hodaka Okajima, and Kentaro Matsumoto, and Yuichiro Hagiya, and Keiji Inoue, and Taro Shuin, and Motowo Nakajima, and Tohru Tanaka, and Shun-Ichiro Ogura
Enhanced lipid metabolism induces the sensitivity of dormant cancer cells to 5-aminolevulinic acid-based photodynamic therapy.
March 2021, Scientific reports,
Taku Nakayama, and Shimpei Otsuka, and Tatsuya Kobayashi, and Hodaka Okajima, and Kentaro Matsumoto, and Yuichiro Hagiya, and Keiji Inoue, and Taro Shuin, and Motowo Nakajima, and Tohru Tanaka, and Shun-Ichiro Ogura
Human glioblastoma stem-like cells accumulate protoporphyrin IX when subjected to exogenous 5-aminolaevulinic acid, rendering them sensitive to photodynamic treatment.
October 2016, Journal of photochemistry and photobiology. B, Biology,
Taku Nakayama, and Shimpei Otsuka, and Tatsuya Kobayashi, and Hodaka Okajima, and Kentaro Matsumoto, and Yuichiro Hagiya, and Keiji Inoue, and Taro Shuin, and Motowo Nakajima, and Tohru Tanaka, and Shun-Ichiro Ogura
Her2 oncogene transformation enhances 5-aminolevulinic acid-mediated protoporphyrin IX production and photodynamic therapy response.
September 2016, Oncotarget,
Taku Nakayama, and Shimpei Otsuka, and Tatsuya Kobayashi, and Hodaka Okajima, and Kentaro Matsumoto, and Yuichiro Hagiya, and Keiji Inoue, and Taro Shuin, and Motowo Nakajima, and Tohru Tanaka, and Shun-Ichiro Ogura
Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX.
June 2007, Lasers in surgery and medicine,
Taku Nakayama, and Shimpei Otsuka, and Tatsuya Kobayashi, and Hodaka Okajima, and Kentaro Matsumoto, and Yuichiro Hagiya, and Keiji Inoue, and Taro Shuin, and Motowo Nakajima, and Tohru Tanaka, and Shun-Ichiro Ogura
[Fluorescence diagnosis and photodynamic therapy with 5-aminolevulinic acid induced protoporphyrin IX in gynecology: an overview].
December 2006, Zentralblatt fur Gynakologie,
Taku Nakayama, and Shimpei Otsuka, and Tatsuya Kobayashi, and Hodaka Okajima, and Kentaro Matsumoto, and Yuichiro Hagiya, and Keiji Inoue, and Taro Shuin, and Motowo Nakajima, and Tohru Tanaka, and Shun-Ichiro Ogura
Effects of Silencing Heme Biosynthesis Enzymes on 5-Aminolevulinic Acid-mediated Protoporphyrin IX Fluorescence and Photodynamic Therapy.
January 2015, Photochemistry and photobiology,
Taku Nakayama, and Shimpei Otsuka, and Tatsuya Kobayashi, and Hodaka Okajima, and Kentaro Matsumoto, and Yuichiro Hagiya, and Keiji Inoue, and Taro Shuin, and Motowo Nakajima, and Tohru Tanaka, and Shun-Ichiro Ogura
Light irradiation increases embryotoxicity of photodynamic therapy sensitizers (5-aminolevulinic acid and protoporphyrin IX) in chick embryos.
January 2001, Reproductive toxicology (Elmsford, N.Y.),
Copied contents to your clipboard!